AKTS

Price-

Market Cap850.27 M

Float486.23 K

Country-

Sector-

Exchange-

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

AKTS

Sector

-

Industry

-

Country

-

Exchange

Vol Avg.

N/A

Inst Own

1.000%

Float & OS

486.23 K / 53.75 M

Cash/Shr

$9.1

Market Cap & Ev

Short Interest

887.2%

Borrow Rate

0.4036%

Days to Cover

11.27

Research Report

Customize research

Recent Articles (8)

Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3

Globe Newswire

Oct 1, 2026, 8:00 AM

Aktis Oncology to Present at Upcoming September Investor Conferences

Globe Newswire

Sep 9, 2026, 8:00 AM

Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026

Globe Newswire

Aug 13, 2026, 4:01 PM

Aktis Oncology to Present at the Jefferies Global Healthcare Conference

Globe Newswire

May 27, 2026, 4:05 PM

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors

Globe Newswire

May 21, 2026, 5:21 PM

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026

Globe Newswire

May 11, 2026, 4:01 PM

Aktis Oncology to Present at the BofA Securities Health Care Conference

Globe Newswire

May 6, 2026, 8:00 AM

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Globe Newswire

May 4, 2026, 4:05 PM

Recent Filings

Type	Title	Date Released

Earnings

Nov

12

Q4 2026 Earnings reportUpcoming

Aug

13

Q3 2026 Earnings report

-0.44%missed

May

11

Q2 2026 Earnings report

-0.38%missed

Mar

30

Q1 2026 Earnings report

-18.19%beat

Dec

3

Q4 2025 Earnings report

-1.39%missed

Nov

14

Q4 2024 Earnings report

-0.04%beat